PubMedCrossRef 14. Hammond TG, Pollard CE: Use of in vitro methods to Torin 2 datasheet predict QT prolongation. Toxicol Appl Pharmacol 2005, 207:446–450.PubMedCrossRef 15. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG: KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Res Treat 2012, 132:391–409.PubMedCrossRef 16. Reddy MV, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA, Akula B, Hoffman BS, Reddy E: Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylaminoacetate (ON

01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem 2011, 54:6254–6276.PubMedCrossRef 17. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

J Clin Invest 2007, 117:218–228.PubMedCentralPubMedCrossRef 18. Broceno C, Wilkie S, Mittnacht S: RB activation defect in tumor cell lines. Proc Natl Acad Sci U S A 2002, 99:14200–14205.PubMedCentralPubMedCrossRef 19. Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K, Xie D, Zhuang L, Deng J, Ma D: Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res 2005, 11:8431–8440.PubMedCrossRef 20. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, Ozturk M: Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. Etomoxir FASEB J 1993, 7:1407–1413.PubMed 21. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH: RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin

Cancer Res 1999, 5:2596–2604.PubMed 22. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noel D, Pillon A, Batimastat Iborra F, et al.: Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006, 26:7561–7574.PubMedCentralPubMedCrossRef 23. Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr Aspartate Relat Cancer 2006, 13:293–325.PubMedCrossRef 24. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T: Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 2008, 7:699–708.PubMedCrossRef 25. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M: Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res Treat 2006, 99:97–101.PubMedCrossRef 26. Vojtesek B, Lane DP: Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 1993,105(Pt 3):607–612.PubMed 27.